Drug Profile
Research programme: hormone modulator therapeutics - Kael-GemVax
Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator KAEL-GemVax
- Class
- Mechanism of Action Hormone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Benign prostatic hyperplasia
Most Recent Events
- 23 Aug 2023 Preclinical development in Benign-prostatic-hyperplasia is still ongoing
- 28 Feb 2019 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in South Korea
- 29 Jan 2015 Preclinical trials in Benign prostatic hyperplasia in South Korea (unspecified route)